Clinical observation and therapeutic evaluation of intravenous pump of recombinant human endostatin combined with TP regimen in treating patients with advanced ovarian cancer

Objectives: To observe the curative effects and adverse reactions of recombinant human (rh)-endostatin injection combined with a TP regimen for treating patients with advanced ovarian cancer. Methods: Fifty-four patients with pathologically confirmed ovarian cancer were randomly divided into a combi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chi Zhang, Wen-Ying Deng, Ning Li, Su-Xia Luo
Formato:	article
Lenguaje:	EN
Publicado:	KeAi Communications Co., Ltd. 2015
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/d183f4d6e047450ab73acaff46931f5f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d183f4d6e047450ab73acaff46931f5f
record_format	dspace
spelling	oai:doaj.org-article:d183f4d6e047450ab73acaff46931f5f2021-12-02T14:35:04ZClinical observation and therapeutic evaluation of intravenous pump of recombinant human endostatin combined with TP regimen in treating patients with advanced ovarian cancer2095-882X10.1016/j.cdtm.2015.08.003https://doaj.org/article/d183f4d6e047450ab73acaff46931f5f2015-09-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2095882X15000493https://doaj.org/toc/2095-882XObjectives: To observe the curative effects and adverse reactions of recombinant human (rh)-endostatin injection combined with a TP regimen for treating patients with advanced ovarian cancer. Methods: Fifty-four patients with pathologically confirmed ovarian cancer were randomly divided into a combined treatment (intravenous pump of rh-endostatin + TP regimen) group and a control (single chemotherapy) group, twenty-seven patients in each group. All patients were given a conventional CT examination. The level of vascular endothelial growth factor (VEGF), the size of tumor before treatment, after 2 cycles and after 4 cycles of treatment were determined for the comparison of curative effects and adverse reactions. Results: The effective rate was 37.0% (10/27) and disease control rate was 63.0% (17/27) in the combined treatment group after 2 cycles of treatment. The effective rate was 25.9% (7/27) and disease control rate was 63.0% (17/27) in the control group. The comparison between these two groups showed no significant differences (P > 0.05). The effective rate was 63.0% (17/27) and disease control rate was 92.6% (25/27) in the combined treatment group after 4 cycles of treatment. The effective rate was 29.6% (8/27) and disease control rate was 63.0% (17/27) in the control group. The effective rate and disease control rate between these two groups after 4 cycles of treatment showed significant differences (P < 0.05). The incidences of cardiovascular toxicity, myelosuppression, sore muscles and joints, alopecia and gastrointestinal reaction was not significantly different between two groups (P > 0.05). Conclusion: The pump delivery of rh-endostatin can down-regulate the expression of VEGF in ovarian cancer and has the better curative effect and slighter adverse reactions. Keywords: Ovarian cancer, Recombinant human endostatin, Intravenous pump, Vascular endothelial growth factor, AngiogenesisChi ZhangWen-Ying DengNing LiSu-Xia LuoKeAi Communications Co., Ltd.articleMedicine (General)R5-920ENChronic Diseases and Translational Medicine, Vol 1, Iss 3, Pp 158-162 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Chi Zhang Wen-Ying Deng Ning Li Su-Xia Luo Clinical observation and therapeutic evaluation of intravenous pump of recombinant human endostatin combined with TP regimen in treating patients with advanced ovarian cancer
description	Objectives: To observe the curative effects and adverse reactions of recombinant human (rh)-endostatin injection combined with a TP regimen for treating patients with advanced ovarian cancer. Methods: Fifty-four patients with pathologically confirmed ovarian cancer were randomly divided into a combined treatment (intravenous pump of rh-endostatin + TP regimen) group and a control (single chemotherapy) group, twenty-seven patients in each group. All patients were given a conventional CT examination. The level of vascular endothelial growth factor (VEGF), the size of tumor before treatment, after 2 cycles and after 4 cycles of treatment were determined for the comparison of curative effects and adverse reactions. Results: The effective rate was 37.0% (10/27) and disease control rate was 63.0% (17/27) in the combined treatment group after 2 cycles of treatment. The effective rate was 25.9% (7/27) and disease control rate was 63.0% (17/27) in the control group. The comparison between these two groups showed no significant differences (P > 0.05). The effective rate was 63.0% (17/27) and disease control rate was 92.6% (25/27) in the combined treatment group after 4 cycles of treatment. The effective rate was 29.6% (8/27) and disease control rate was 63.0% (17/27) in the control group. The effective rate and disease control rate between these two groups after 4 cycles of treatment showed significant differences (P < 0.05). The incidences of cardiovascular toxicity, myelosuppression, sore muscles and joints, alopecia and gastrointestinal reaction was not significantly different between two groups (P > 0.05). Conclusion: The pump delivery of rh-endostatin can down-regulate the expression of VEGF in ovarian cancer and has the better curative effect and slighter adverse reactions. Keywords: Ovarian cancer, Recombinant human endostatin, Intravenous pump, Vascular endothelial growth factor, Angiogenesis
format	article
author	Chi Zhang Wen-Ying Deng Ning Li Su-Xia Luo
author_facet	Chi Zhang Wen-Ying Deng Ning Li Su-Xia Luo
author_sort	Chi Zhang
title	Clinical observation and therapeutic evaluation of intravenous pump of recombinant human endostatin combined with TP regimen in treating patients with advanced ovarian cancer
title_short	Clinical observation and therapeutic evaluation of intravenous pump of recombinant human endostatin combined with TP regimen in treating patients with advanced ovarian cancer
title_full	Clinical observation and therapeutic evaluation of intravenous pump of recombinant human endostatin combined with TP regimen in treating patients with advanced ovarian cancer
title_fullStr	Clinical observation and therapeutic evaluation of intravenous pump of recombinant human endostatin combined with TP regimen in treating patients with advanced ovarian cancer
title_full_unstemmed	Clinical observation and therapeutic evaluation of intravenous pump of recombinant human endostatin combined with TP regimen in treating patients with advanced ovarian cancer
title_sort	clinical observation and therapeutic evaluation of intravenous pump of recombinant human endostatin combined with tp regimen in treating patients with advanced ovarian cancer
publisher	KeAi Communications Co., Ltd.
publishDate	2015
url	https://doaj.org/article/d183f4d6e047450ab73acaff46931f5f
work_keys_str_mv	AT chizhang clinicalobservationandtherapeuticevaluationofintravenouspumpofrecombinanthumanendostatincombinedwithtpregimenintreatingpatientswithadvancedovariancancer AT wenyingdeng clinicalobservationandtherapeuticevaluationofintravenouspumpofrecombinanthumanendostatincombinedwithtpregimenintreatingpatientswithadvancedovariancancer AT ningli clinicalobservationandtherapeuticevaluationofintravenouspumpofrecombinanthumanendostatincombinedwithtpregimenintreatingpatientswithadvancedovariancancer AT suxialuo clinicalobservationandtherapeuticevaluationofintravenouspumpofrecombinanthumanendostatincombinedwithtpregimenintreatingpatientswithadvancedovariancancer
_version_	1718391160765939712

Clinical observation and therapeutic evaluation of intravenous pump of recombinant human endostatin combined with TP regimen in treating patients with advanced ovarian cancer

Ejemplares similares